| 臺大學術典藏 |
2019 |
Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma
|
Lin Z.-Z.; CHIUN HSU; Jeng Y.-M.; Hu F.-C.; Pan H.-W.; Wu Y.-M.; Hsu H.-C.; Cheng A.-L. |
| 國立成功大學 |
2019 |
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
|
Qin, S.;Chan, S.L.;Sukeepaisarnjaroen, W.;Han, G.;Choo, S.P.;Sriuranpong, V.;Pan, H.;Yau, T.;Guo, Y.;Chen, M.;Ren, Z.;Xu, J.;Yen, C.-J.;Lin, Z.-Z.;Manenti, L.;Gu, Y.;Sun, Y.;Tiedt, R.;Hao, L.;Song, W.;Tanwandee, Tanwandee T. |
| 國立成功大學 |
2019 |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim, R.D.;Sarker, D.;Meyer, T.;Yau, T.;Macarulla, T.;Park, J.-W.;Choo, S.P.;Hollebecque, A.;Sung, M.W.;Lim, H.-Y.;Mazzaferro, V.;Trojan, J.;Zhu, A.X.;Yoon, J.-H.;Sharma, Sharma S.;Lin, Z.-Z.;Chan, S.L.;Faivre, S.;Feun, L.G.;Yen, C.-J.;Dufour, J.-F.;Palmer, D.H.;Llovet, J.M.;Manoogian, Manoogian M.;Tugnait, M.;Stransky, N.;Hagel, M.;Kohl, N.E.;Lengauer, C.;Sherwin, C.A.;Schmidt-Kittler, O.;Hoeflich, K.P.;Shi, H.;Wolf, B.B.;Kang, Y.-K. |
| 臺大學術典藏 |
2018-09-10T18:05:00Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao, Y.-Y.;Chen, B.-B.;Ou, D.-L.;Lin, Z.-Z.;Hsu, C.-H.;Wang, M.-J.;Cheng, A.-L.;Hsu, C.; BANG-BIN CHEN; ANN-LII CHENG |
| 臺大學術典藏 |
2018-09-10T07:20:08Z |
EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment
|
Huang, C.-L.;Yang, C.-H.;Yeh, K.-H.;Hu, F.-C.;Chen, K.-Y.;Shih, J.-Y.;Lin, Z.-Z.;Yu, C.-J.;Cheng, A.-L.;Yang, P.-C.; Chong-Jen Yu; KUN-HUEI YEH; JIN-YUAN SHIH; ANN-LII CHENG |
| 國立臺灣科技大學 |
2017 |
Reweighting forest for extreme multi-label classification
|
Lin, Z.-Z.;Dai, B.-R. |
| 臺大學術典藏 |
2017 |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Morikawa H.; Maki Y.; Tanaka T.; Ohtomo T.; Schwartz L.; Smith-Jones P.M.; Frenette C.; O’Neil B.; Shao Y.-Y.; Wan P.; Ma J.; Gansukh B.; Lyashchenko S.K.; Pandit-Taskar N.; Ruan S.; Beylergil V.; O’Donoghue J.; Yen C.-J.; CHIH-HUNG HSU; Abou-Alfa G.K.; Abou-Alfa G.K.;Yen C.-J.;Chih-Hung Hsu;O’Donoghue J.;Beylergil V.;Ruan S.;Pandit-Taskar N.;Gansukh B.;Lyashchenko S.K.;Ma J.;Wan P.;Shao Y.-Y.;Lin Z.-Z.;Frenette C.;O’Neil B.;Schwartz L.;Smith-Jones P.M.;Ohtomo T.;Tanaka T.;Morikawa H.;Maki Y.;Ohishi N.;Chen Y.-C.;Agajanov T.;Boisserie F.;Di Laurenzio L.;Lee R.;Larson S.M.;Cheng A.-L.;Carrasquilo J.A.; Lin Z.-Z. |
| 臺大學術典藏 |
2017 |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.;Bang-Bin Chen;Ou D.-L.;Lin Z.-Z.;Hsu C.-H.;Wang M.-J.;Cheng A.-L.;Hsu C.; Shao Y.-Y.; BANG-BIN CHEN; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2017 |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yu C.-J.; Yang J.C.H.; Lin C.-C.; Lin Z.-Z.; Chen J.-S.; JIN-YUAN SHIH; Chen K.-Y.; Ho C.-C.; Liao W.-Y.; Yao Z.-H.; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Jin-Yuan Shih;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.H.;Yu C.-J. |
| 國立成功大學 |
2017 |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Abou-Alfa, G.K.;Yen, C.-J.;Hsu, C.-H.;O’Donoghue, J.;Beylergil, V.;Ruan, S.;Pandit-Taskar, N.;Gansukh, B.;Lyashchenko, S.K.;Ma, J.;Wan, P.;Shao, Y.-Y.;Lin, Z.-Z.;Frenette, C.;O’Neil, B.;Schwartz, L.;Smith-Jones, P.M.;Ohtomo, T.;Tanaka, Tanaka T.;Morikawa, H.;Maki, Y.;Ohishi, N.;Chen, Y.-C.;Agajanov, T.;Boisserie, F.;Di, Laurenzio L.;Lee, R.;Larson, S.M.;Cheng, A.-L.;Carrasquilo, J.A. |
| 國立臺灣大學 |
2016 |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma (HCC): biomarker exploration
|
Shao, Y-Y.; Chen, B-B.; Lin, Z-Z.; Hsu, C-H.; Wang, M-J.; Cheng, A-L.; Hsu, C.; 邵幼雲; 林宗哲; 鄭安理; 陳邦斌; 徐志宏; 許駿 |
| 臺大學術典藏 |
2016 |
Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: A nationwide cohort study
|
Chen K.-H.; YU-YUN SHAO; Chen H.-M.; Lin Y.-L.; Lin Z.-Z.; Lai M.-S.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2015 |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
Kuo H.-Y.;Lin Z.-Z.;Kuo R.;Shau W.-Y.;Lai C.-L.;Yang Y.-Y.;Shao Y.-Y.;Hsu C.;Wen-Fang Cheng;Cheng A.-L.;Yang J.C.H.;Lai M.-S.; Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; WEN-FANG CHENG; Cheng A.-L.; Yang J.C.H.; Lai M.-S. |
| 臺大學術典藏 |
2015 |
Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan
|
Lai C.-L.; Lin Z.-Z.; Cheng A.-L.; Lai M.-S.; Yeh Y.-C.; Chen H.-M.; Yeh K.-H.; Shao Y.-Y.; CHIH-HUNG HSU; Shao Y.-Y.;Chih-Hung Hsu;Yeh K.-H.;Chen H.-M.;Yeh Y.-C.;Lai C.-L.;Lin Z.-Z.;Cheng A.-L.;Lai M.-S. |
| 臺大學術典藏 |
2014 |
Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer
|
Cheng A.-L.; Yeh K.-H.; Su W.-C.; Chao Y.; Shen Y.-C.; Li C.-P.; Yen C.-J.; CHIUN HSU; Lin Y.-L.; Lin Z.-Z.; Chen L.-T. |
| 臺大學術典藏 |
2014 |
Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma
|
Ou D.-L.; Chang C.-J.; Jeng Y.-M.; Lin Y.-J.; Lin Z.-Z.; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; CHIUN HSU; Cheng A.-L. |
| 臺大學術典藏 |
2013 |
A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy
|
YU-YUN SHAO; Liang P.-C.; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lin Z.-Z. |
| 臺大學術典藏 |
2013 |
A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy
|
Shao Y.-Y.; Liang P.-C.; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; CHIUN HSU; Cheng A.-L.; Lin Z.-Z. |
| 國立臺灣大學 |
2012 |
HOSPITAL VOLUMES OF PERCUTANEOUS RADIOFREQUENCY ABLATION ASSOCIATED WITH ITS TREATMENT OUTCOMES FOR PATIENTS WITH HEPATOCELLULAR CARCINOMA
|
Shao, Y. -Y.; Lu, L. -C.; Kuo, R. N. C.; Lin, Z. -Z.; Yeh, Y. -C.; Shau, W. -Y.; Hsu, C. -H.; Cheng, A. -L.; Lai, M. -S.; 邵幼雲; 林宗哲; 鄭安理; 徐志宏; 呂理駿 |
| 國立臺灣大學 |
2012 |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
Shao, Y-Y; Lu, L-C; Lin, Z-Z; Hsu, C.; Shen, Y-C; Hsu, C-H; Cheng, A-L; 邵幼雲; 林宗哲; 鄭安理; 徐志宏; 許駿; 呂理駿 |
| 臺大學術典藏 |
2012 |
Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy
|
Lin Z.-Z.; Hsu C.; Hu F.-C.; YU-YUN SHAO; Chang D.-Y.; Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L. |
| 臺大學術典藏 |
2012 |
The impact of diabetes mellitus on prognosis of early breast cancer in Asia
|
Chen W.-W.; YU-YUN SHAO; Shau W.-Y.; Lin Z.-Z.; Lu Y.-S.; Chen H.-M.; Kuo R.N.C.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2012 |
Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma
|
Shau W.-Y.; Shao Y.-Y.; Yeh Y.-C.; Lin Z.-Z.; Kuo R.; Hsu C.-H.; Chiun Hsu; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2012 |
Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma
|
Shau W.-Y.; Shao Y.-Y.; Yeh Y.-C.; Lin Z.-Z.; Kuo R.; Hsu C.-H.; CHIUN HSU; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2011 |
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy
|
Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; CHIUN HSU; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2010 |
Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC
|
Lin Z.-Z.;Yung-Ming Jeng;Hu F.-C.;Pan H.-W.;Tsao H.-W.;Lai P.;Lee P.;Cheng A.-L.;Hsu H.-C.; Lin Z.-Z.; YUNG-MING JENG; Hu F.-C.; Pan H.-W.; Tsao H.-W.; Lai P.; Lee P.; Cheng A.-L.; Hsu H.-C. |
| 臺大學術典藏 |
2010 |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
|
Hsu C.-H.; Yang T.-S.; CHIUN HSU; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; Lin Z.-Z.; Chao T.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2009 |
The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma
|
Lin Z.-Z.; Hsu H.-C.; Hsu C.-H.; Yeh P.-Y.; Huang C.-Y.F.; Huang Y.-F.; Chen T.-J.; Kuo S.-H.; CHIUN HSU; Hu F.-C.; Jeng Y.-M.; Chung Y.; Cheng A.-L. |
| 臺大學術典藏 |
2008 |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
CHIH-HSIN YANG; Yang P.-C; Cheng A.-L; Lin C.-C; Hsu C.-H; Yu C.-J; Chang Y.-C; Chih-Hsin Yang;Yang P.-C;Cheng A.-L;Lin C.-C;Hsu C.-H;Yu C.-J;Chang Y.-C;Hsu C;Lin Z.-Z; Lin Z.-Z; Hsu C |
| 國立臺灣科技大學 |
2007 |
Ferro/anti-ferroelectric liquid crystal doped with high concentration ferroelectric nanoparticles
|
Lee J.-Y.; Lin Z.-Z.; Xiao Y.-Z. |
